UCB
Budget
€200 — €0
EP Access
0
accredited persons
Staff
4
0.95 FTE
EU Grants
None
Mission & Goals
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9 000 people in approximately 40 countries, the company generated revenue of € 6.1 billion in 2024. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
EU Legislative Interests
Any health, pharmaceutical and/or life sciences policy stemming from the European institutions, especially in relation to EU Pharmaceutical, Industrial, IP, Research, Digital and Trade strategies. This includes initiatives related to Antimicrobial resistance (AMR), ATMP Regulation, Brexit, Clinical Trials, Data Protection, AI and Data Strategies, EU industrial policy, EU IP policy incl. SPCs, EU Relative Efficacy Assessment, EU research policy, EU trade policy, Healthcare Systems, HTA & Market Access, EU research programs such as IMI and Horizon Europe, Medical Devices, Orphan Medicinal Products and Paediatric Regulations, Patient access to innovation, Patient safety, Pharmaceuticals in the environment, Sustainability & Sustainable Development Goals.
Interests Represented
Promotes their own interests or the collective interests of their members
Member Of
EFPIA = European Federation of Pharmaceutical Industries and Associations (http://efpia.eu/)
Organisation Members
N/A
Commissioner Meetings
No recorded meetings with EU commissioners.